Asian American patients taking Crestor, a cholesterol-lowering drug made by AstraZeneca, may be at greater risk of muscle injury because of Crestor than the general public, the Food and Drug Administration warned on Tuesday.

The announcement comes after AstraZeneca revised the package insert for Crestor, advising physicians to consider using lower starting doses of the drug in some individuals as a means of reducing the risk of rhabdomyolysis. The revised label includes dosing instructions for Asian Americans, as wells as patients on cyclosporine and patients with severe kidney disease.

Crestor is part of a class of drugs called statins that have been linked to rhabdomyolysis (serious muscle damage) and other types of kidney failure.

Despite the warning, the FDA said it “believes that potential benefits of statin drugs (including Crestor) when used as labeled and indicated for the treatment of elevated cholesterol (hypercholesterolemia) outweigh their potential risks and provide an important treatment option for millions of Americans at risk of heart disease.”.

(via U.S. Food and Drug Administration)